Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-623 and ABBV-992 in B-cell Malignancies
NCT04804254Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Apr 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of ABBV-623 and ABBV-992 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 4 more (6 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With Adverse Events up to 25 months, Maximum Observed Plasma Concentration of ABBV-623 up to 96 weeks and 4 more. Started Apr 2021; status: terminated.
02
Drugs
ABBV-623ABBV-992
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04804254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04804254.